Publication: Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy
dc.contributor.coauthor | Topkan, Erkan | |
dc.contributor.coauthor | Yildirim, Berna Akkus | |
dc.contributor.coauthor | Guler, Ozan Cem | |
dc.contributor.coauthor | Parlak, Cem | |
dc.contributor.coauthor | Selek, Ugur | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Pehlivan, Berrin | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T23:28:00Z | |
dc.date.issued | 2015 | |
dc.description.abstract | Purpose: To investigate the safety and efficacy of single-dose 8-Gy palliative chest reirradiation (CRI) in metastatic non-small cell lung cancer (M-NSCLC) patients with painful thoracic failures (TF) within the previous radiation portal. Patients and Methods: We retrospectively analyzed the clinical data of 78 M-NSCLC patients who received single-dose 8-Gy CRI for painful TF after concurrent chemoradiation therapy to a total radiation dose of 52 to 66 Gy between 2007 and 2012. Primary endpoints included significant pain relief (SPR) defined as a >= 2 point decrement in the Visual Analogue Scale for Pain inventory (VAS-P), time to pain relief, and duration of pain control. Secondary objectives were survival and prognostic factors. Results: Treatment was well tolerated, with only 5.1% grade 3 pneumonitis and 1.3% grade 2 esophagitis. Pre-CRI median and post-CRI minimum VAS-P were 7 and 3 (P < .001), respectively. SPR was noted in 67 (85.9%) patients, and only 3 (3.9%) scored progressive pain. Median time to lowest VAS-P and duration of pain control were 27 days and 6.1 months, respectively. Median overall survival (OS) was 7.7 months, and the 1-year OS rate was 26.5%. On multivariate analyses, lower Eastern Cooperative Oncology group score (1-2; P < .001), absence of anemia (P = .001), and fewer metastatic sites (1-2; P < .001) were found to be associated with longer OS. Conclusions: Single-dose 8-Gy CRI provides safe, effective, and durable pain palliation for TF in radically irradiated M-NSCLC patients. Because of its convenience, lower cost, and higher comfort, the present protocol can be considered an appropriate option for patients with limited life spans. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 4 | |
dc.description.openaccess | NO | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 91 | |
dc.identifier.doi | 10.1016/j.ijrobp.2014.12.010 | |
dc.identifier.eissn | 1879-355X | |
dc.identifier.issn | 0360-3016 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-84924678251 | |
dc.identifier.uri | https://doi.org/10.1016/j.ijrobp.2014.12.010 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/11811 | |
dc.identifier.wos | 351733500017 | |
dc.keywords | Outcomes | |
dc.keywords | Carcinoma | |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartof | International Journal of Radiation Oncology Biology Physics | |
dc.subject | Oncology | |
dc.subject | Radiology | |
dc.subject | Nuclear medicine | |
dc.subject | Medical imaging | |
dc.title | Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Pehlivan, Berrin | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |